News

LifeArc grant to fund research into repurposing therapies for MND

LifeArc, a U.K.-based independent medical research charity, is offering £5 million (about $6 million) to scientists around the world as part of a grant program to tackle motor neuron disease (MND) using repurposed or combined medicines. The program is part of the Motor Neuron Disease Translational Challenge, which…

Relyvrio reduces inflammatory biomarkers in ALS: CENTAUR data

Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. Data from the Phase 2 study (NCT03127514) demonstrated that reductions in…

Coya, Dr. Reddy’s collaborate to advance COYA 302 for ALS

Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress chronic and sustained inflammation — will now be exclusively marketed by Dr. Reddy’s Laboratories in the U.S., Canada, and the U.K., as well as in the European Union, should…

ALS Association helping to move ORY-4001 into animal studies

The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…